Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 10, 1997, Pages 2238-2243

  Wallace, Thomas L ^a   Paetznick, Victor ^b   Cossum, Paul A ^a   Lopez Berestein, Gabriel ^b   Rex, John H ^c   Anaissie, Elias ^b,d  

^a Antigenics Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; NYSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG FORMULATION; DRUG POTENCY; FUNGICIDAL ACTIVITY; MALE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

EID: 0030864107     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.10.2238     Document Type: Article

References (56)

1. Anaissie, E. J., V. Paetznick, R. Proffitt, J. Adler-Moore, and G. P. Bodey, 1991. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. 10:665-668.
2. Andriole, V. T., P. Miniter, D. George, D. Kordick, and T. F. Patterson. 1992. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Clin. Infect. Dis. 14(Suppl. 1):S134-S138.
3. Bennett, J. E. 1994. Antifungal agents, p. 1165-1181. In A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (ed.), Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. McGraw-Hill, New York, N.Y.
4. Bennett, J. E. 1994. Aspergillosis, p. 854-856. In K. J. Isselbacher, E. Braunwald, J. D. Wilson, J. B. Martin, A. S. Fauci, and D. L. Kasper (ed.), Harrison's principles of internal medicine, 13th ed. McGraw-Hill, New York, N.Y.
5. Boutati, E. I., H. C. Maltezou, G. Lopez-Berestein, S. E. Vartivarian, and E. J. Anaissie. 1995. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies, abstr. LM22, p. 330. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Broughton, M. C., M. Bard, and N. D. Lees. 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34:75-83.
7. Brown, R., E. L. Hazen, and A. Mason. 1953. Effect of fungicidin (nystatin) in mice injected with lethal mixtures of aureomysin and Candida albicans. Science 117:609-610.
8. Cahill, K. M., A. M. Mofty, and T. P. Kawaguchi. 1967. Primary cutaneous aspergillosis. Arch. Dermatol. 96:545-547.
9. Campbell, C. C., E. T. O'Dell, and G. B. Hill. 1955. Therapeutic activity of nystatin in experimental systemic mycotic infections. Antibiot. Annu. 1955: 858-862.
10. Chen, W. C., D.-L. Chou, and D. S. Feingold. 1978. Dissociation between ion permeability and the lethal action of polyene antibiotics on Candida albicans. Antimicrob. Agents Chemother. 13:914-917.
11. Drouchet, E., J. Schwarz, and E. Bingham. 1956. Evaluation of the action of nystatin on Histoplasma capsulatum in vitro and in hamsters and mice. Antibiot. Chemother. (Washington, D.C.) 6:23-35.
12. Fendler, J. H., and A. Romero. 1977. Liposomes as drug carriers. Life Sci. 20:1109-1120.
13. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371-373.
14. Gero, S., and J. Szekely. 1958. Pulmonary moniliasis treated with nystatin aerosol. Lancet ii:1229-1230.
15. Ghannoum, M. A., J. H. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
16. Gordon, L. E., C. E. Smith, and D. S. Wedin. 1955. Nystatin (Mycostatin®) therapy in experimental coccidioidomycosis. Am. Rev. Tuberc. Pulm. Dis. 72:64-70.
17. Guaschino, S., G. Micheline, E. Stola, G. Lombardi, A. Spinillo, and P. Viale. 1986. Mycotic vaginitis in pregnancy: a double evaluation of the susceptibility to the main antimycotic drugs of isolated species. Biol. Res. Pregnancy 7:20-22.
18. Hammond, S. M. 1977. Biological activity of polyene antibiotics. Prog. Med. Chem. 14:106-179.
19. Hazen, E. L., R. Brown, and A. Mason. 1953. Protective action of fungicidin (nystatin) in mice against virulence enhancing activity of oxytetracycline on Candida albicans. Antibiot. Chemother. (Washington, D.C.) 3:1125-1128.
20. Hazen, E. L., and R. Brown. 1951. Fungicidin, an antibiotic produced by a soil actinomycete. Proc. Soc. Exp. Biol. Med. 76:93-97.
21. Hebeka, E., and M. Solotorovsky. 1965. Development of resistance to polyene antibiotics in Candida albicans. J. Bacteriol. 89:1533-1539.
22. Jensen, H. E. 1994. Animal models in mycology, p. 169-194. In P. Svendsen and J. Hau (ed.), Handbook of laboratory science, vol. II. CRC Press, Boca Raton, Fla.
23. Kinsky, S. C. 1963. Comparative responses of mammalian erythrocytes and microbial protoplasts to polyene antibiotics and vitamin A. Arch. Biochem. Biophys. 102:180-188.
24. Korting, H. C., M. Ollert, A. Georgii, and M. Froschl. 1988. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J. Clin. Microbiol. 26:2626-2631.
25. Kozinn, P. J., C. L. Taschdjian, D. Dragutsky, and A. Minsky. 1957. Treatment of cutaneous candidiasis in infancy and childhood with nystatin and amphotericin B. Antibiot. Annu. 1957:128-134.
26. Lehan, P. H., J. L. Yates, C. A. Brasher, H. W. Larsh, and M. L. Furcolow. 1957. Experiences with the therapy of sixty cases of deep mycotic infections. Dis. Chest 32:597-614.
27. Lopez-Berestein, G. 1988. Liposomes as carriers of antifungal drugs. Antifungal Drugs 544:590-597.
28. Manning, L. K., and L. Robertson. 1959. Medical memorandum: a case of aspergillosis treated with nystatin. Br. Med. J. 1:345-346.
29. Meade, R. H. 1979. Drug therapy reviews: clinical pharmacology and therapeutic use of antimycotic drugs. Am. J. Hosp. Pharm. 36:1326-1334.
30. Mehta, R. T., R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein. 1987. Formulation, toxicity, and antifungal activity in vitro liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1897-1900.
31. Mehta, R. T., R. L. Hopfer, T. McQueen, R. L. Juliano, and G. Lopez-Berestein. 1987. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31:1901-1903.
32. 31a. National Archives and Records Administration. 1995. Current good manufacturing practice for finished pharmaceuticals, p. 82-102. In Code of federal regulations. National Archives and Records Administration, Washington, D.C.
33. 31b. National Institutes of Health. 1985. Public Health Service guide for the care and use of laboratory animals. Publication 86-23. National Institutes of Health, Bethesda, Md.
34. Newcomer, V. D., E. T. Wright, T. H. Sternberg, J. H. Graham, R. H. Wier, and R. O. Egeberg. 1955. Evaluation of nystatin in the treatment of coccidioidomycosis in man, p. 260-267. In T. H. Sternberg and V. D. Newcomer (ed.), Therapy of fungus diseases. Little, Brown and Co., Boston, Mass.
35. Ng, T. T., and D. W. Denning. 1995. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155:1093-1098.
36. Oehling, A., M. Giron, and M.-L. Subira. 1975. Aerosol chemotherapy in bronchopulmonary candidiasis. Respiration 32:179-184.
37. Pace, H. R., and S. I. Schantz. 1956. Nystatin (mycostatin) in the treatment of monilial and nonmonilial vaginitis. JAMA 22:268-271.
38. Plotnick, H., and S. Cerri. 1957. Treatment of oral histoplasmosis by local injection with nystatin. JAMA 28:346-348.
39. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
40. Procknow, J. J., and C. G. Loosli. 1958. Treatment of deep mycoses. Arch. Intern. Med. 101:765-802.
41. Robinson, R. C. V. 1957. Systemic moniliasis treated with mycostatin. J. Investig. Dermatol. 24:375.
42. Sinclair, A. J., A. H. Rossof, and C. A. Coltman. 1978. Recognition and successful management in pulmonary aspergillosis in leukemia. Cancer 42: 2019-2024.
43. Solotorovsky, M., G. Quabeck, and S. Winsten. 1958. Antifungal activity of Candidin, nystatin, euclin, and stilbamidine against experimental infections in the mouse. Antibiot. Chemother. (Washington, D.C.) 8:364-371.
44. Stanley, V. C., and M. P. English. 1965. Some effects of nystatin on the growth of four Aspergillus species. J. Gen. Microbiol. 40:107-118.
45. Stark, J. E. 1967. Allergic pulmonary Aspergillus successfully treated with inhalations of nystatin. Dis. Chest 51:96-99.
46. Stern, J. C., M. K. Shah, and F. E. Lucente. 1988. In vitro effectiveness of 13 agents in otomycosis and review of the literature. Laryngoscope 98:1173-1177.
47. Stevens, D. R. 1994. Overview of amphotericin B colloidal dispersion (Amphocil). J. Infect. 28(Suppl. 1):45-49.
48. Terrell, C. L., and C. E. Hughes. 1992. Antifungal agents for deep-seated mycotic infections. Mayo Clin. Proc. 67:69-91.
49. Than, K. M., K. S. Naing, and M. Min. 1980. Otomycosis in Burma, and its treatment. Am. J. Trop. Med. Hyg. 29:620-623.
50. Thomas, A. H. 1986. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J. Antimicrob. Chemother. 17:269-279.
51. Tollemar, J., S. Anderson, O. Ringden, and G. A. Tyden. 1992. Retrospective clinical comparison between antifungal treatment with amphotericin B (Ambisome) and conventional amphotericin B in transplant recipients. Mycoses 35:215-220.
52. 49a. U.S. Department of Agriculture. 1966. Laboratory Animal Welfare Act, Publication L-89-544. U.S. Department of Agriculture, Washington, D.C.
53. Vedder, J. S., and W. F. Schor. 1969. Primary disseminated pulmonary aspergillosis with metastatic skin nodules. JAMA 209:1191-1195.
54. Wallace, T. L., and G. Lopez-Berestein. Nystatin and Nyotran™ (liposomal nystatin). In V. L. Yu, T. C. Merigan, S. Barriere, and N. J. White (ed.), Antimicrobial chemotherapy, in press. Williams and Wilkins, Baltimore, Md.
55. Weinstein, J. N., and L. D. Leserman. 1984. Liposomes as drug carriers in cancer chemotherapy. Pharmacol. Ther. 24:207-233.
56. Woods, R. A., M. Bard, I. E. Jackson, and D. J. Drutz. 1974. Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. J. Infect. Dis. 129:53-58.